Article
Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1.
Blood - 7 Apr 2016
Gu Shengqing, Chan Wayne W, Mohi Golam, Rosenbaum Joel, Sayad Azin, Lu Zhibin, Virtanen Carl, Li Shaoguang, Neel Benjamin G, Van Etten Richard A
Abstract excerpt
Tyrosine kinase inhibitors (TKIs) directed against BCR-ABL1, the product of the Philadelphia (Ph) chromosome, have revolutionized treatment of patients with chronic myeloid leukemia (CML). However, acquired resistance to TKIs is a significant clinical problem in CML, and TKI therapy is much less effective against Ph(+)B-cell acute lymphoblastic leukemia (B-ALL). BCR-ABL1, via phosphorylated Tyr177, recruits the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
